Pinnacle Financial Partners, Inc.
Position in GALT — Galectin Therapeutics Inc
CIK 2082866
ATLANTA, GA
Position in GALT
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$116,203
-$83,477 QoQ
Shares Held
41,650
-13.2% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GALT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pinnacle Financial Partners, Inc. holds $41,348,368 across 16 Biotechnology names. GALT ranks #15 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,226 | $8,585,176 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
85,881 | $5,550,489 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
20,180 | $5,212,897 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
202,282 | $4,725,307 | |
| 5 | RPRX |
Royalty Pharma plc
|
86,614 | $4,154,872 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
22,865 | $3,864,642 | |
| 7 | VSTM |
Verastem, Inc.
|
495,266 | $2,624,909 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
34,909 | $1,972,009 |
All Filings in GALT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $116,203 | 41,650 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $199,680 | 48,000 | Shares | Defined | 2026-02-18 | |
| No filing history on record for this holder in this stock. | ||||||